Results 191 to 200 of about 60,444 (298)

Molecular Glue Degraders Redefining Targeted Therapies From Discovery to Therapeutic Applications

open access: yesMedComm – Oncology, Volume 5, Issue 1, March 2026.
Molecular glue degraders (MGDs) constitute an emerging class of therapeutic agents poised to revolutionize the paradigm of targeted drug discovery. By reprogramming E3 ubiquitin ligases to degrade proteins of interest (POI) via a transient formation of a ternary complex mediated by protein–protein interactions, MGDs surpass the intrinsic limitations of
Jinfeng Wen   +3 more
wiley   +1 more source

The Evolution of Pneumocystis jirovecii Pneumonia Prophylaxis for Pediatric Patients With Extracranial Solid Tumors: A Review of Historical Insights and Future Directions

open access: yesPediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
ABSTRACT Pneumocystis jirovecii pneumonia (PJP) remains a modern‐day complication for pediatric patients receiving treatment for extracranial solid tumors (ST), highlighting the need for reconsideration of our current approach toward PJP prophylaxis. This critical review aims to evaluate both universal and risk‐stratified approaches to PJP prophylaxis ...
Kriti Kumar   +8 more
wiley   +1 more source

Society for Maternal‐Fetal Medicine Consult Series #76: Cancer in pregnancy

open access: yesPregnancy, Volume 2, Issue 2, March 2026.
Abstract Approximately one in 1000 pregnancies is complicated by the diagnosis of cancer each year, and the incidence of cancer among reproductive‐age individuals is increasing. Management of a pregnant person with cancer can be complex and warrants a multidisciplinary approach to care.
Society for Maternal‐Fetal Medicine (SMFM)   +6 more
wiley   +1 more source

Population PK/PD Modeling for Evaluation of Intertwining Effects of Drug and Disease on Thrombocytopenia in Acute Leukemias

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT In hematological malignancies, thrombocytopenia is a frequent feature of the disease. Anti‐leukemic therapies are known to impact thrombocytopenia, which is commonly selected as a dose‐limiting toxicity in early clinical trials. However, given the concurrent myelosuppressive effects of the drug and the underlying leukemia, it can be difficult ...
Tomás Sou   +2 more
wiley   +1 more source

Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy [PDF]

open access: yes, 2017
IIZUKA Junpei   +6 more
core   +2 more sources

CMV Preventive and Treatment Studies in Children Undergoing Haematopoietic Stem Cell Transplant: A Systematic Review

open access: yesReviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT Cytomegalovirus (CMV) is one of the most important infectious causes of morbidity and mortality in children undergoing haematopoietic stem cell transplant (HSCT). However, the evidence for preventing and treating CMV disease in children in this context remains limited. We sought to review the current available evidence regarding the prevention
Lara Fusani   +7 more
wiley   +1 more source

Predicting chemotherapy-induced myelosuppression in colorectal cancer: An interpretable, machine learning-based nomogram. [PDF]

open access: yesWorld J Gastroenterol
Liu YM   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy